PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Enoxaparin - VTE treatment in patients unable to take oral anticoagulants

PAD Profile : Enoxaparin - VTE treatment in patients unable to take oral anticoagulants

Keywords :
Venous Thromboembolism, Low molecular weight heparins, LMWH
Brand Names Include :
Clexane, Inhixa, enoxaparin BECAT, Arovi

Traffic Light Status

Status 1 of 1.

Status :
Blue
Important
Formulations :
  • Subcutaneous injection (sc)
Important Information :
Prescribe by brand. RSCH / SASH = Inhixa. ASPH = Clexane. Specialist initiation and at least one month supply before transfer to primary care (excluding obstetric and cancer patients)
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
23 February 2021
East Surrey MOG

East Surrey / SASH local recommendation:

Inhixa is the preferred brand of enoxaparin at Surrey and Sussex Healthcare NHST trust. Enoxaparin is a biological medicine and must be prescribed by brand in line with MHRA guidance.

See Inhixa communication document for GPs below

04 December 2019
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Area Prescribing Committee recommends the use of low weight molecular heparins (LWMH) for the treatment of VTE in those patients who are unable to take oral anticoagulants (excluding obstetric patients and those on current cancer chemotherapy).

LMWH will be considered BLUE (no information sheet) on the traffic light system for the above indications (see below for exclusions).

The specialist should prescribe the initial 1st month of drug treatment. Primary care can take over prescribing upon receipt of an agreed treatment plan from the specialist, which must include details of drug dosage, possible side-effects, and action to take if problems arise, as per local guidance.

LMWH will be considered RED for obstetric use and in patients on current cancer chemotherapy.

Primary care prescriber should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication

22 January 2018
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

Enoxaparin is a biological medicine and must be prescribed by brand in line with MHRA guidance. Note; differences in the mechanisms for operation in needle guard between presentations of enoxaparin.

06 November 2024
NW Surrey Medicines Optimisation Group

North West Surrey / ASPH local recommendation:

Ashford & St Peter's Hospitals NHS Foundation Trust are changing the brand of enoxaparin from Clexane to Inhixa (equivalent biosimilar product).

Enoxaparin is a biological medicine and must be prescribed by brand in line with MHRA guidance.

There are limited indications for which enoxaparin should be prescribed in primary care but, where indicated, North West Surrey in conjunction with ASPH are recommending that practices change to using the Inhixa® brand for all new initiations to support patient safety.

See the "NWS Enoxaparin brand switch" document for details

Associated BNF Codes

02. Cardiovascular System
02.08.01. Parenteral anticoagulants
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More